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HealtH Care resourCe use aND DireCt Costs assoCiateD witH Fragile 
X syNDrome (FXs) iN tHe uNiteD states
Vekeman F.1, Gauthier-Loiselle M.1, Faust E.2, Lefebvre P.1, Lahoz R.3, Duh M.S.2, Sacco P.4
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Objectives: FXS is the most common inherited form of intellectual disability and is 
associated with comorbidities that impair functioning and adaptive behavior. This 
study is aimed at evaluating the incremental direct health care costs and resource uti-
lization associated with FXS using administrative health care claims data. MethOds: 
Using the Optum Health Reporting and Insights Employer database covering 1999-
2012, subjects < 65 years old with ≥ 1 FXS diagnosis (ICD-9-CM: 759.83) and ≥ 6 months 
of continuous enrollment prior to the first observed FXS diagnosis were matched 
with up to 5 non-FXS controls using high-dimensional propensity score matching. 
Individuals were followed until the end of continuous enrollment in the health plan. 
All-cause and FXS-related costs and resource utilization stratified by hospitalizations, 
emergency room (ER), outpatient, and home care visits were examined. Results: 
590 FXS individuals (mean[median] age: 25.7[27]; female: 54.1%; employee: 32%) and 
2,950 non-FXS controls (mean[median] age: 25.7[27]; female: 52.1%; employee: 32%) 
were identified. Significant differences were observed between FXS and non-FXS in 
the all-cause per-patient per-year (PPPY) incidence of hospitalizations (0.414 vs. 0.237; 
incidence rate ratio [IRR] [95% CI]: 1.75[1.51-2.02]), outpatient visits (14.345 vs. 9.078; 
IRR: 1.58[1.54-1.62]), and home care visits (1.817 vs. 0.348; IRR: 5.22[4.80-5.69]). Similar 
results were found for FXS-related hospitalizations (0.206 vs. 0.092; IRR: 2.23[1.80-
2.77]), outpatient visits (4.929 vs. 1.976; IRR: 2.49[2.39-2.61]), and home care visits (0.341 
vs. 0.029; IRR: 11.70[9.09-15.06]). FXS subjects were also associated with significantly 
higher PPPY all-cause health care costs (total[SD]: $14,674[47,163] vs. $5,110[18,378]; 
hospitalization: $4,507[18,141] vs. $1,328[10,203]; outpatient: $4,730[12,538] vs. 
$2,394[10,515]; drugs: $2,331[6,226] vs. $844[2,244]; p< .01 for all) and FXS-related costs 
(total: $5,890[16,541] vs. $1,744[10,149]; hospitalization: $2,730[13,628] vs. $788[9,506]; 
outpatient: $1,799[4,243] vs. $555[1,510]; drugs: $1,008[2,999] vs. $197[1,030]; p< .01 for 
all), compared to non-FXS controls. cOnclusiOns: The economic burden associated 
with FXS is significant and underscores the need to improve outcomes of individu-
als with FXS.
PND20
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1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 
3St. Vincent’s University Hospital, Dublin, Ireland
Objectives: Multiple Sclerosis (MS) has significant financial consequences for 
health care systems, individual patients and households, and the society in general. 
This study examines the distribution of MS costs and resource utilisation across cost 
categories and from various perspectives, as MS disability increases. MethOds: A 
total of 214 patients with MS were recruited from a specialised MS outpatient clinic 
in Dublin, Ireland, to participate in an interview-based study on MS-related resource 
consumption and costs. Mean annual direct medical, direct non-medical and indi-
rect costs per patient were calculated, stratified by MS disability: mild (n= 114), 
moderate (n= 72) and severe (n= 27). Results: Participants were 66% female; mean 
(sd) age 47.6(12.75) years; mean (sd) EDSS score 3.6(2.6); 53% relapsing-remitting 
MS. Mean annual direct costs increased as MS disability increased from ~€ 10,000 
in mild disease, more than five fold to ~€ 56,000 in severe MS. Direct costs exceed 
indirect costs in mild and severe MS, driven by costly disease-modifying therapies 
and professional home-help respectively. In contrast, indirect costs dominate in 
moderate MS (~€ 32,000 indirect vs. ~€ 13,000 direct) due primarily to early retire-
ment. Disease-modifying therapies account for 76% of total direct costs in mild MS. 
A total of 74%-96% of all direct costs are borne by the health care payer in Ireland. 
Remaining costs are incurred by patients, their families or other non-health care 
organisations predominantly relating to non-medical resources such as living-aids, 
home-modifications and home-help. cOnclusiOns: MS is associated with high 
levels of health care resource consumption and costs, which increase with disability. 
The majority of direct costs in our study are borne by the health care payer. However 
out-of-pocket spending at the individual patient level and the contribution of other 
organisations can be significant, particularly in severe disease. There is potential 
to significantly reduce the economic burden of MS through interventions which 
prevent progression to severe disability, support independent living at home and 
maintain labour force participation.
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tHe aNNual treatmeNt aND reHabillitatioN Costs oF PatieNts witH 
ParaPlegia iN tHe Private HealtH Care settiNg iN greeCe
Tzovolou K., Geitona M.
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Objectives: To examine the annual resource use and related treatment costs for 
patients with paraplegia in Greece in 2011. MethOds: This was a prospective study, 
which recorded data from all inpatient and outpatient visits to Olympion Hospital, a 
private rehabilitation center in Patras, during 2011. Patient files, which recorded the 
patients’ demographic, clinical and economic/ cost data, were created. Direct costs 
included medical and pharmaceutical costs, lab tests and direct non-medical costs, 
which were retrieved through the Center’s IT system. Indirect cost data consisted 
of the loss of individual and family income and were elicited via face-to-face or tel-
ephone interviews with the patients or their relatives. Each patient participating in 
the study signed an informed consent. Results: A total of 300 patients were treated 
in the rehabilitation center in 2011, of which 36 (12%) suffered from paraplegia. Of 
these, 20 were treated in the inpatient setting and 16 in the outpatient setting. The 
total average annual cost of treating patients with paraplegia was estimated at 
€ 101,228; the average costs of the inpatient and outpatient settings were € 86,699 
(€ 74,296 direct cost + € 12,403 indirect cost) and € 14,529 (€ 9,445 direct cost and € 5,084 
indirect cost) respectively. The mean number of hospitalization days for inpatients 
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Natalizumab For raPiDly evolviNg severe relaPsiNg-remittiNg 
multiPle sClerosis (resrrms) PatieNts: 5-year buDget imPaCt aNalysis 
(bia) From tHe braziliaN PubliC Payer PersPeCtive
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Objectives: Multiple sclerosis (MS) is a neurodegenerative disease associated 
with long-term disability and significant economic impact. With the addition 
of new agents for the treatment of MS (e.g. natalizumab), there is a need to 
evaluate the relative value of newer therapies in terms of cost, given health 
care resource constraints in Brazil. This analysis considered just the indication 
for rapidly evolving severe relapsing-remitting multiple sclerosis (RESRRMS) 
patients (≥ 2 disabling relapses per year, and ≥ 1 gadolinium-enhancing lesions 
on brain magnetic resonance imaging or a significant increase in T2 lesion load). 
Brazilian reimbursement guidelines recommend natalizumab only as 3rd line 
treatment for MS. A budget impact analysis (BIA) has been created to analyze 
the impact of introducing natalizumab in RESRRMS treatment in Brazilian Public 
Healthcare System (SUS). MethOds: BIA was based on a Markov model with 
monthly cycles and 5-year time horizon with MS epidemiological data obtained 
from Brazilian public database (DATASUS). The model compared current MS 
treatment options reimbursed by the Brazilian government – interferons-betas, 
glatiramer acetate and natalizumab (3rd line) with an alternative scenario with 
1st line natalizumab. Results: The number of Brazilian patients eligible for 
REHARRMS treatment was estimated to be 1,574, 532 and 110 patients for 1st, 2nd 
and 3rd line treatment, respectively, in the first year. Compared to the current 
scenario, the inclusion of natalizumab in the reimbursement protocol for 1st 
line shows potential savings of USD 729.1K, 524.6K, 360.3K, 200.6K and 83.6K for 
5 consecutive years. cOnclusiOns: The inclusion of natalizumab as RESRRMS 
treatment option is estimated to yield savings of USD 1.9 M in five years for MS 
treatment in SUS.
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buDget imPaCt oF switCHiNg PramiPeXole immeDiate release to 
PramiPeXole eXteNDeD release iN treatmeNt oF ParkiNsoN’s Disease; 
PersPeCtive oF tHe soCial seCurity iNstitutioN
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Objectives: Budget impact analysis of switching Pramipexole Immediate Release 
(IR) to Pramipexole Extended Release (ER) in treatment of Parkinson’s Disease in 
the Turkish health care setting from a Social Security Institution’s (SSI) perspec-
tive. MethOds: Based upon a literature review demonstrating that, Pramipexole 
ER is similar to Pramipexole IR in efficacy and safety in treatment of Parkinson’s 
Disease (non-inferiority), budget impact analyses were performed using Microsoft 
Excel (2007). Results: The switch from IR to ER was analyzed for the following 
formulations 0.75MG /1.50MG /3.00MG /4.50MG per day and patient. The daily 
pill burden per patient was reduced from 3 to 1 and 6 to 1 for 0,75MG /1,5MG 
/3,0MG and 4,5MG respectively. The total annual treatment cost per patient was 
reduced by 2.91%, 6.25%, 1.74% and 3.30% for 0.75MG, 1.50MG, 3.00MG and 4.50MG 
respectively. cOnclusiOns: The findings of this study indicate that, switching 
Parkinson’s Patients from Pramipexole IR to ER will not result in an additional 
budget impact for the Turkish health care system from a SSI perspective. However, 
further research needs to be conducted in order to explore the potential implica-
tions of compliance benefits and if they can be translated into long-term savings. 
No local effectiveness data was available at the time this analysis was performed. 
Potential benefits in patients’ adherence were not considered.
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HealtH Care resourCe utilizatioN aND Cost amoNg Natalizumab 
iNitiators witH multiPle sClerosis iN tHe uNiteD states
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Objectives: To evaluate MS-related health care resource utilization and costs 
prior to and after initiating natalizumab in the US. MethOds: A retrospective 
administrative claims analysis was conducted using the Truven Health MarketScan 
Commercial and Medicare supplemental databases to identify adults diagnosed 
with MS (ICD-9-CM 340) who initiated natalizumab between January 1, 2007 and 
December 31, 2010 (first claim is the index date). Patients had ≥ 24 months of 
continuous enrollment (12 months before [pre-period] and 12 months after [post-
period] the index date) and remained on natalizumab for the 12 month post-
period. Patients with and without other disease modifying treatment (DMT) during 
the pre-period were examined. Patient characteristics, MS-related inpatient stays 
and corticosteroid use were described in the pre- and post-periods. Results: The 
1458 patients in this study had a mean age of 45.2 years (standard deviation 10.5) 
and 74% were female. The majority (70.1%) used a DMT during the pre-period. After 
initiating natalizumab, there was a significant reduction in percentage of patients 
with MS-related inpatient stays (7.6% vs. 2.4%, p< 0.001), MS-related inpatient costs 
(median $12,078 vs. $9,784, p< 0.001) and length of stay (7.12 days vs. 6.26 days, 
p= 0.005). Reduction in percentage of patients with MS-related inpatient stays 
and costs were numerically higher for patients without DMTs in the pre-period 
(-6.2% and -$1,496 respectively) compared with those with a DMT in the pre-
period (-4.8% and -$1,262, respectively). Compared to the pre-period, there were 
significant reductions in IV and oral corticosteroid use for natalizumab initiators 
(-60.1% and -52.9%, respectively, p< 0.001 for both). These reductions correspond 
to a mean corticosteroid cost per patient reduction of $101 across all natalizumab 
users (p< 0.001). cOnclusiOns: The initiation of natalizumab was associated with 
significant decreases in MS-related inpatient stays and corticosteroid use with 
corresponding decreases in length of stay and costs among natalizumab users 
with and without DMTs in the prior year.
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Netherlands from a societal perspective. MethOds: Health care, patient and fam-
ily and other use of resources for five different categories of side-effects were 
measured by means of a questionnaire. Respondents were patients with epilepsy 
who experienced at least one side-effect due to antiepileptic treatment in the 
last 12 months. Results: Based on data from 203 chronic epilepsy patients, the 
overall societal costs of common side-effects in 2012 are estimated to be € 20,751 
(CI: 15,049-27,196) per patient per year in the base case analysis. These societal 
costs exist of: mean health care costs (€ 4,458), mean patient and family costs (i.e. 
informal care and out of pocket expenses) (€ 10,526) and mean other costs (i.e. pro-
ductivity and daily routine losses) (€ 5,761). Examining the different categories of 
side-effects separately, ranging from the most to the least expensive category, the 
cost estimates were as follows: other side-effects (€ 13,228), behavioral side-effects 
(€ 9,689), general health side-effects (€ 7,454), cognitive side-effects (€ 7,285) and 
cosmetic side-effects (€ 2,845) per patient per year. Subgroup analyses showed sig-
nificant differences in costs between patients using monotherapy and those using 
polytherapy when looking at cognitive and cosmetic side-effects. cOnclusiOns: 
These estimates should be considered in the overall assessment of the economic 
impact of a pharmacotherapy.
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HealtH Care resourCes utilizatioN iN alzHeimer’s Disease: aN 
aNalysis witH tHe QuebeC ProviNCial Drug reimbursemeNt Program 
Database
Lachaine J.1, Lambert-Obry V.1, Dionne P.A.2
1University of Montreal, Montreal, QC, Canada, 2Pfizer Canada, Kirkland, QC, Canada
Objectives: To assess resource utilization before and after the development of 
Alzheimer’s disease (AD), using the Quebec provincial drug reimbursement program 
database (RAMQ). MethOds: This study included patients covered by the RAMQ 
who had at least one diagnosis of AD (ICD-9 code 3310) or have received at least 
one script for an AD medication (donepezil, rivastigmine, galantamine or meman-
tine) from January, 1985 to December, 2011. A control group of patients without AD 
was created on a 1:1 ratio and matched for age, gender and geographic location. 
The index date was defined as the date of the first AD diagnosis or the first script 
for AD medication whichever comes first. Health care resource costs were ana-
lyzed in terms of emergency room, outpatient clinic, intensive care unit and physi-
cian’s visits, hospitalizations and long-term care, plus AD medications and other 
medications costs. Annual health care costs were reported for the 5-years before 
and the 5-years after the index date. Results: Data were obtained for a random 
sample of 34,086 AD patients (mean age of 78.5 years [SD= 8.0], 65.2% females). 
Before the index date, health care costs were similar between AD patients and the 
control group, except for the year preceding AD. Indeed, cost per patient for this 
year increased from CDN$5,126 to CDN$8,839 for the AD group and from CDN$4,466 
to CDN$5,212 for the control group (72.4% vs. 16.7% increase respectively). For the 
5-year period after the index date, costs were significantly higher for AD patients 
with an average cost per patient per year of CDN$9,364 vs. CDN$5,864 for the control 
group (mean difference of CDN$3,500,p< 0.001). cOnclusiOns: AD significantly 
increases health care resource costs, including medical resources and medications. 
Costs generated by AD patients cumulate over time leading to a major difference in 
long-term costs compared to non-AD patients.
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Cost eFFeCtiveNess oF aPomorPHiNe iN tHe treatmeNt oF aDvaNCeD 
ParkiNsoN Disease iN tHe uk aND germaNy: results From a 
multiCouNty DeCisioN aNalytiC moDel
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Objectives: Parkinson Disease (PD) is the second commonest cause of neuro-
logical disability and affected approximately 5.2 million men and women world-
wide. Continuous subcutaneous apomorphine (CSAI) represents an alternative 
treatment option of advanced PD with motor fluctuation. The purpose of this 
analysis was to estimate the cost-effectiveness of CSAI compared with Levodopa/
carbidopa intestinal gel (LCIG), Deep-Brain-Stimulation (DBS) and Standard-of-care 
(SOC). MethOds: We developed a multicounty Markov-Model to simulate the long-
term consequences, disease progression (Hoehn&Yahr-stages 3-5, percentage of 
waking-time in the OFF-state), complications and adverse-events. Complications 
are different for the alternatives (e.g. pump problems in case of LCIG, temporary/
permanent complications in case of DBS). We include moderate and severe adverse-
events and death. Monte-Carlo-simulation accounted for uncertainty. The model 
includes 25 health-states. Probabilities were derived from RCT and open-label stud-
ies; direct costs (2012) from published sources from the payer’s perspective (NHS and 
German health care systems). QALYs, life-years (LYs) and costs were projected over 
a life-time horizon and discounted according the national guidelines. Results: UK 
life-time costs associated with CSAI amounts to 70,258 £ and generates 2.85 QALYs 
and 6.28 LYs (106,530 € , 2.92 QALYs and 6.49 LYs for Germany). Costs associated 
with LCIG are 117,121 £, achieves 3.06 QALYs and 6.93 LYs (178,405 € , 3.18 QALYs and 
7.18 LYs for Germany). The incremental-cost per QALY gained (ICER) was 223,052 £ 
(281,089 € ). Costs for DBS are 88,361.61 £, associated with 2.75 QALYs and 6.38 LYs 
(121,988 € , 2.85 QALYs and 6.61 LYs for Germany). CSAI dominates DBS. SOC associ-
ated UK costs are 68,082.92 £; 2.62 QALYs and 5.76 LYs were reached (91,588 € , 2.7 
3QALYs and 6 LYs for Germany). cOnclusiOns: CSAI is a cost-effective treatment 
alternative, reducing OFF-time and improving quality-of-life and is associated with 
a cost-advantage.
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Cost-eFFeCtiveNess oF somatroPiN aDmiNistratioN witH iNCreaseD 
aDHereNCe Due to moNitoriNg ComPareD to NoN-moNitoreD 
aDmiNistratioN iN PatieNts witH growtH HormoNe DeFiCieNCy
Vitova V., Tichopad A.
CEEOR s.r.o., Prague, Czech Republic
were 178. The key cost driver for inpatients was daycare (hospitalization, medical 
and nursing care, therapies). cOnclusiOns: The annual cost of treating patients 
with paraplegia in the private health care sector in Greece is high. This study is the 
first cost study in this disease area and additional studies should be undertaken in 
order to acquire a more complete picture of the cost of managing disease, in both 
the private and public health care sectors.
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Objectives: PD-LID, a complication of L-Dopa treatment, is associated with inabil-
ity to perform daily living activities, reduction in quality of life and increase in 
health care costs. Limited data are currently available on the burden of this dis-
ease. LIDIA describes medical and non-medical resource utilization and economic 
impact of PD-LID patients from payer and society perspective according to LID 
severity: mild (mAIMS score< 8), moderate (mAIMS [8-12]) and severe (mAIMS> 12) 
patients. MethOds: This observational, prospective, longitudinal, multicentre 6 
month-study was conducted by French neurologists specialized in Parkinson’s dis-
ease (PD). PD patients taking L-dopa for at least 3 years were included, with PD-LID 
present for more than 3 months and for more than 25% of the time. Results: 
Thirty-three neurologists included 186 patients (mean 68 years old, 52% women) 
with mean mAIMS score at 10. PD-LID patients were mainly followed by their neu-
rologists (96%) and general practitioner (GP) (84%) with more non-medical follow-up 
for severe patients. Almost 60% had at least one biological or radiological exami-
nation, only 31% required transport. All patients received L-Dopa (including 32% 
long-acting), and 69% dopaminergic agonists. Only 21% had at least one hospitali-
zation and over 40% needed home layout and mobility equipment. Most patients 
(70%) were assisted by a caregiver (24h/week), 43% required external assistance (6h/
week), 22% received an invalidity allowance. Total costs represent 35117€ , 33640€ and 
43739€ in respectively mild, moderate and severe patients (on average per patient/
year). Non-medical costs (transportations, paid external help, caregivers time, mobil-
ity equipment, home layout) are the major cost drivers (80%), including caregiver 
help (70%), followed by medical (consultations, treatments, hospitalizations)(15%) 
and indirect costs (allowances and work stoppages)(5%). cOnclusiOns: The LIDIA 
study confirms that in this disabling disease, the economic burden is mainly sup-
ported by the patient family, with the payer part being 23%. Economic burden is 
greater in patients with severe dyskinesia.
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HerPes zoster iN euroPe: a review oF eviDeNCe DoCumeNtiNg 
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Objectives: Herpes zoster (HZ) and its most common complication post-herpetic 
neuralgia (PHN: pain persisting months after the rash onset) are associated with 
substantial burden of disease. There is a sharp increase in incidence from the 
age of 50, impacting individuals, their relatives and society. The objective of our 
work was to conduct a critical review documenting the Humanistic, Economic and 
Societal Burden of HZ in Europe. MethOds: Systematic searches were conducted in 
Medline, EMBASE, PSYCHINFO, EconLit, HEED and CRD databases, using a combina-
tion of search terms in title and abstracts. Articles, published from 2000 onwards, 
were selected for full review by two independent researchers in accordance with 
predefined eligibility criteria. Results: From a review of 1448 abstracts, 42 eligible 
articles, were identified which reported data concerning health care resource use 
(n= 26), direct costs (n= 21), indirect costs (n= 14), impact on health-related qual-
ity of life (HRQoL) (n= 21) and impact on caregivers (n= 3). Findings across studies 
highlight that levels of pain severity and the presence of PHN are associated with 
greater impairments in HRQoL and higher costs of management. At least 50% of 
employed patients missed work due to the disease. While the incidence of HZ and 
PHN increase with age, age was not a key driver of overall costs for HZ and PHN. 
Specifically, while direct costs (e.g. GP, specialists, medications, hospitalisations) 
tend to be higher for older patients, indirect costs (e.g. work time missed) are higher 
for younger patients. cOnclusiOns: Available evidence highlights that HZ and 
PHN result in significant humanistic and economic burden for patients, health care 
systems and wider societies. There is a tendency to focus upon health care resource 
use and the direct costs of management which may result in an underestimation 
of the true burden of HZ and PHN, which is also expected to grow with the ageing 
European population.
PND24
siDe-eFFeCts oF aNtiePilePtiC Drugs: tHe eCoNomiC burDeN
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Objectives: Epilepsy is a brain disorder which is characterized by recurrent 
unprovoked seizures. The outward effect of seizures can be as dramatic as a 
wild trashing movement or as mild as a brief loss of awareness. To reduce fre-
quency and severity of seizures, antiepileptic drugs are potentially an effective 
treatment for patients with epilepsy. However, side-effects are common. The 
negative consequences of side-effects can lead to treatment ranging from minor 
care to very expensive hospitalization. This cost analysis has been conducted 
to provide insight into the costs of side-effects due to antiepileptic drugs in The 
